C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of chimeric antigen receptor (CAR) T cells and CAR natural killer (NK) cells in the multiple myeloma setting.
As with every therapy, there are pros and cons to the use of NK cells and CAR T cells, according to Landgren. One of the challenges when it comes to CAR T cells is the practical delivery of these agents since patients usually need to be hospitalized. These patients also have to undergo procedures if they are being treated with autologous CAR T cells. This therapy implies patients have to come in, go through CAR T-cell harvesting, and then come back about a month later when they can receive these CAR T cells in the hospital.
Landgren says that with allogeneic CAR T cells, there is no need to harvest the cells because they come from donors. That is also true for treatment with NK cells.